← All stocks

Outlook Therapeutics, Inc.

OTLK Net buying
CIK 0001649989 #4052 in the set updated 17 Sep 2026
Bought (12 mo)
$7.87M
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
+$7.87M
+$7.87M against sales at will

By person

7 insiders · 10 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Sukhtian Ghiath M.
Director
$7.50M (2)
+$7.50M
24,617,320
$24.37M
+165.7%
HILZINGER KURT J
Director
$176.52K (1)
+$176.52K
423,655
$419.42K
+1,691%
Sukhtian Faisal Ghiath
Director
$150.00K (2)
+$150.00K
220,972
$218.76K
+6,399%
Haddadin Yezan Munther
Director
$39.11K (2)
+$39.11K
66,167
$65.51K
+1,989%
THURMAN RANDY H
Director
$2.15K (1)
+$2.15K
5,593
$5.54K
+843.2%
Jahr Robert Charles
Chief Executive Officer
(1)
$0.00
151,515
$150.00K
KENYON LAWRENCE A
Chief Financial Officer
(1)
$0.00
106,956
$105.89K
+11,206%

No percentages here. This company's share count has moved by a factor of 9.8 over the window, from 24,905,635 to 243,447,554 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
KENYON LAWRENCE A
14 Aug 2026
Chief Financial Officer
Buy
101,010
no price
Jahr Robert Charles
14 Aug 2026
Chief Executive Officer
Buy
151,515
no price
Sukhtian Ghiath M.
12 Aug 2026
Director
Buy indirect
2,525,252
$0.99
$2.50M
Sukhtian Faisal Ghiath
29 Jul 2026
Director
Buy
95,398
$1.05
$100.00K
Haddadin Yezan Munther
2 Jun 2026
Director
Buy
29,000
$0.83
$24.15K
Sukhtian Ghiath M.
28 May 2026
Director
Buy indirect
8,539,709
$0.59
$5.00M
Sukhtian Faisal Ghiath
27 May 2026
Director
Buy
122,174
$0.41
$50.01K
HILZINGER KURT J
26 May 2026
Director
Buy
400,000
$0.44
$176.52K
THURMAN RANDY H
26 May 2026
Director
Buy
5,000
$0.43
$2.15K
Haddadin Yezan Munther
26 May 2026
Director
Buy
34,000
$0.44
$14.96K

What was left out

Form 4 filings counted 21
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 2
Shares from compensation/vesting 0
History held since 14 Nov 2016